SCHEMBL3016871

SCHEMBL3016871

COc1ccc(OC)c(Cc2csc(N3CCC(S(=O)(=O)c4ccccc4Br)CC3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.37
LMNA P02545 3/20 0.37
POLB P06746 1/20 0.37
ADRB2 P07550 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CTSS P25774 1/20 0.37
TP53 P04637 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
HTR1A P08908 1/20 0.36
SLC6A4 P31645 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
HTT P42858 2/20 0.35
USP2 O75604 1/20 0.35
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007519 0.93 MAPT (0.37) MAPTLMNARAB9ASMN1; SMN2CTSS
SCHEMBL3015248 0.91 CTSS (0.39) MAPTLMNARECQLRAB9ACTSS
SCHEMBL3003638 0.90 CTSS (0.40) MAPTLMNAPOLBADRB2TSHR
SCHEMBL3014447 0.90 ALDH1A1 (0.43) MAPTLMNAPOLBADRB2TSHR
SCHEMBL3008649 0.89 ALDH1A1 (0.38) MAPTLMNAPOLBADRB2TSHR
SCHEMBL3019361 0.89 RAB9A (0.39) MAPTLMNAPOLBADRB2TSHR
SCHEMBL3014359 0.88 DRD2 (0.42) MAPTLMNAPOLBADRB2TSHR
SCHEMBL3006262 0.88 CTSS (0.42) MAPTLMNAPOLBADRB2TSHR
SCHEMBL3011978 0.87 ALDH1A1 (0.44) MAPTLMNAPOLBADRB2TSHR
SCHEMBL3015110 0.87 L3MBTL1 (0.43) MAPTLMNATSHRRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885POLB 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.